Patents by Inventor Sai Man LIU
Sai Man LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230285521Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.Type: ApplicationFiled: January 4, 2023Publication date: September 14, 2023Applicant: IPSEN BIOINNOVATION LIMITEDInventors: Shilpa PALAN, Sai Man LIU, Gavin Stephen HACKETT
-
Patent number: 11753633Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.Type: GrantFiled: August 26, 2016Date of Patent: September 12, 2023Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, IPSEN PHARMA S.A.S.Inventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute, Keith Alan Foster, Shilpa Palan, Sai Man Liu
-
Patent number: 11642399Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.Type: GrantFiled: March 8, 2019Date of Patent: May 9, 2023Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Shilpa Palan, Sai Man Liu, Gavin Stephen Hackett
-
Publication number: 20230025090Abstract: The present invention relates to chimeric neurotoxins with enhanced properties and their use in therapy.Type: ApplicationFiled: July 12, 2022Publication date: January 26, 2023Applicant: IPSEN BIOPHARM LIMITEDInventor: Sai Man LIU
-
Patent number: 11434265Abstract: The present invention relates to chimeric neurotoxins with enhanced properties and their use in therapy.Type: GrantFiled: May 5, 2017Date of Patent: September 6, 2022Assignee: IPSEN BIOPHARM LIMITEDInventor: Sai Man Liu
-
Publication number: 20210246175Abstract: The present invention provides engineered clostridial toxins comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pi) of the engineered clostridial toxin to a value that is at least 0.2 pi units higher than the pi of an otherwise identical clostridial toxin lacking said at least one amino acid modification, and wherein said at least one amino acid modification is not located in the clostridial toxin binding domain (Hc domain). Also provided are medical uses of the engineered clostridial toxins.Type: ApplicationFiled: April 19, 2021Publication date: August 12, 2021Applicant: IPSEN BIOINNOVATION LIMITEDInventors: Dina Brady ANDERSON, Gavin Stephen HACKETT, Sai Man LIU
-
Patent number: 11034947Abstract: The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pI) of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the pI of an otherwise identical clostridial toxin lacking said at least one amino acid modification. Also provided are corresponding uses of the engineered clostridial toxin in therapy.Type: GrantFiled: February 6, 2018Date of Patent: June 15, 2021Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Dina Brady Anderson, Gavin Stephen Hackett, Sai Man Liu
-
Patent number: 11014968Abstract: Method for preventing or treating a condition or disease in a subject comprising administering to the subject an engineered clostridial toxin comprising at least one amino acid modification that increases the isoelectric point of the toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification.Type: GrantFiled: February 25, 2020Date of Patent: May 25, 2021Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Dina Brady Anderson, Gavin Stephen Hackett, Sai Man Liu
-
Publication number: 20200291073Abstract: Method for preventing or treating a condition or disease in a subject comprising administering to the subject an engineered clostridial toxin comprising at least one amino acid modification that increases the isoelectric point of the toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification.Type: ApplicationFiled: February 25, 2020Publication date: September 17, 2020Applicant: Ipsen Bioinnovation LimitedInventors: Dina Brady ANDERSON, Gavin Stephen HACKETT, Sai Man LIU
-
Patent number: 10647750Abstract: Engineered clostridial toxins comprising an amino acid modification that increases the isoelectric point of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification, wherein the modification is not located in the clostridial toxin binding domain (HC domain).Type: GrantFiled: January 9, 2015Date of Patent: May 12, 2020Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Dina Brady Anderson, Gavin Stephen Hackett, Sai Man Liu
-
Publication number: 20190201505Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.Type: ApplicationFiled: March 8, 2019Publication date: July 4, 2019Applicant: IPSEN BIOINNOVATION LIMITEDInventors: Shilpa PALAN, Sai Man Liu, Gavin Stephen HACKETT
-
Patent number: 10307468Abstract: Methods for producing di-chain BoNT/A from single chain BoNT/A using Lys-C followed by purification using a hydrophobic surface.Type: GrantFiled: April 29, 2015Date of Patent: June 4, 2019Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Shilpa Palan, Sai Man Liu, Gavin Stephen Hackett
-
Publication number: 20190127427Abstract: The present invention relates to chimeric neurotoxins with enhanced properties and their use in therapy.Type: ApplicationFiled: May 5, 2017Publication date: May 2, 2019Inventor: Sai Man Liu
-
Publication number: 20180298366Abstract: The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pI) of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the pI of an otherwise identical clostridial toxin lacking said at least one amino acid modification. Also provided are corresponding uses of the engineered clostridial toxin in therapy.Type: ApplicationFiled: February 6, 2018Publication date: October 18, 2018Inventors: Dina Brady ANDERSON, Gavin Stephen HACKETT, Sai Man LIU
-
Publication number: 20180244731Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.Type: ApplicationFiled: August 26, 2016Publication date: August 30, 2018Inventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute, Keith Alan Foster, Shilpa Palan, Sai Man Liu
-
Publication number: 20180141982Abstract: Engineered clostridial toxins comprising an amino acid modification that increases the isoelectric point of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification, wherein the modification is not located in the clostridial toxin binding domain (HC domain).Type: ApplicationFiled: January 9, 2015Publication date: May 24, 2018Inventors: Dina Brady ANDERSON, Gavin Stephen HACKETT, Sai Man LIU
-
Publication number: 20180117128Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.Type: ApplicationFiled: April 29, 2015Publication date: May 3, 2018Applicant: Ipsen Bioinnovation LimitedInventors: SHILPA PALAN, SAI MAN LIU, GAVIN Stephen HACKETT
-
Patent number: 9920310Abstract: The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pI) of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the pI of an otherwise identical clostridial toxin lacking said at least one amino acid modification. Also provided are corresponding uses of the engineered clostridial toxin in therapy.Type: GrantFiled: July 9, 2014Date of Patent: March 20, 2018Assignee: Ipsen BioInnovation, LimitedInventors: Dina Brady Anderson, Gavin Stephen Hackett, Sai Man Liu
-
Publication number: 20160369256Abstract: The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pI) of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the pI of an otherwise identical clostridial toxin lacking said at least one amino acid modification. Also provided are corresponding uses of the engineered clostridial toxin in therapy.Type: ApplicationFiled: July 9, 2014Publication date: December 22, 2016Inventors: Dina ANDERSON, Gavin HACKETT, Sai Man LIU